These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 6092115

  • 21. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
    Chang RS, Lotti VJ.
    Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin.
    Rodriguez M, Galas MC, Lignon MF, Mendre C, Laur J, Aumelas A, Martinez J.
    J Med Chem; 1989 Oct; 32(10):2331-9. PubMed ID: 2477546
    [Abstract] [Full Text] [Related]

  • 23. Conformational analysis of possible biologically active (receptor-bound) conformations of peptides derived from cholecystokinin, cerulein and little gastrin and the opiate peptide, Met-enkephalin.
    Pincus MR, Murphy RB, Carty RP, Chen J, Shah D, Scheraga HA.
    Peptides; 1988 Oct; 9 Suppl 1():145-52. PubMed ID: 2856638
    [Abstract] [Full Text] [Related]

  • 24. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
    Silvente Poirot S, Hadjiivanova C, Escrieut C, Dufresne M, Martinez J, Vaysse N, Fourmy D.
    Eur J Biochem; 1993 Mar 01; 212(2):529-38. PubMed ID: 8444190
    [Abstract] [Full Text] [Related]

  • 25. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
    Knapp RJ, Vaughn LK, Fang SN, Bogert CL, Yamamura MS, Hruby VJ, Yamamura HI.
    J Pharmacol Exp Ther; 1990 Dec 01; 255(3):1278-86. PubMed ID: 2262906
    [Abstract] [Full Text] [Related]

  • 26. Characterization of receptors for cholecystokinin and related peptides in mouse cerebral cortex.
    Saito A, Goldfine ID, Williams JA.
    J Neurochem; 1981 Aug 01; 37(2):483-90. PubMed ID: 6267205
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Analysis of the behavioral activity of C- and N-terminal fragments of cholecystokinin octapeptide.
    Crawley JN, St-Pierre S, Gaudreau P.
    J Pharmacol Exp Ther; 1984 Aug 01; 230(2):438-44. PubMed ID: 6086888
    [Abstract] [Full Text] [Related]

  • 34. Characteristics of 125I-Bolton-Hunter labelled cholecystokinin binding in human brain.
    Cross AJ, Slater P, Skan W.
    Neuropeptides; 1988 Aug 01; 11(2):73-6. PubMed ID: 3368039
    [Abstract] [Full Text] [Related]

  • 35. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS, Chen TB, Bock MG, Freidinger RM, Chen R, Rosegay A, Lotti VJ.
    Mol Pharmacol; 1989 Jun 01; 35(6):803-8. PubMed ID: 2733696
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Binding of 125I-CCK-8 and 125I-gastrin-I to dispersed chief cells from guinea-pig stomach.
    Sutliff VE, Cherner JA, Jensen RT, Gardner JD.
    Biochim Biophys Acta; 1990 Apr 09; 1052(1):9-16. PubMed ID: 2322595
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.